Altered deoxyribonuclease activity in cancer cells and its role in non toxic adjuvant cancer therapy with mixed vitamins C and K3

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2727-2732

  Taper, Henryk S ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Adjuvant therapy; DNAses; Prognosis; Review; Vitamin C; Vitamin K3

Indexed keywords

ASCORBIC ACID; ASPARAGINASE; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; DEOXYRIBONUCLEASE II; DOXORUBICIN; FLUOROURACIL; MENADIONE; PROCARBAZINE; TUMOR PROMOTER; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE SULFATE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CELL DEATH; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REACTIVATION; HUMAN; IMMUNOCYTOMA; IN VITRO STUDY; IN VIVO STUDY; LIVER TUMOR; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; CHEMOTHERAPY, ADJUVANT; DEOXYRIBONUCLEASES; HUMANS; NEOPLASMS; VITAMIN K 3;

EID: 55749095717     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Taper HS: La détection histochimique de la dé soxyribonuclease alkaline. Ann Histochim 13: 301-317, 1968.
2. Vorbrodt A: Histochemical studies on the intracellular localization of acid deoxyribonuclease. J Histochem Cytochem 9: 647-655, 1961.
3. Loiselle JM and Carrier R: Désoxyribonucléase sérique chez les cancéreux. Rev Canad Biol 22: 41-46, 1963.
4. Daoust R and Amano H: Ribonuclease and deoxyribonuclease activities in experimental and human tumors by histochemical substrate film method. Cancer Res 23: 131-134, 1963.
5. Taper HS: The relation between the histochemical activity of nucleases and neoplasms in rat and man. Vander, Louvain, 1975.
6. Taper HS, Brucher JM and Fort L: Alkaline and acid nuclease activity in the tumors of the human central nervous system. (Histochemical study). Cancer 28: 482-490, 1971.
7. Taper HS: L'activité des nucleases et phosphatases acides et alcalines dans les tumeurs rénales induites chez le rat par la diméthylnitrosamine (Etude histochimique). Path Eur 2: 406-420, 1967.
8. Fort L, Taper HS and Brucher JM: Gastric carcinogenesis induced in rats by methylnitrosourea (MNU). Morphology and histochemistry of nucleases. Z Krebsforsch 81: 51-62, 1974.
9. Taper HS, Fort L and Brucher JM: Histochemical activity of alkaline and acid nucleases in rat liver parenchyma during N-nitrosomorpholine carcinogenesis. Cancer Res 31: 913-916, 1971.
10. Taper HS and Bannasch P: Histochemical correlation between glycogen, nucleic acids and nucleases in preneoplastic lesions of rat liver after short-term administration of N-nitrosomorpholine Z Krebsforsch 87: 53-65, 1976.
11. Taper HS and Bannasch P: Histochemical correlation between so-called megalocytosis and preneoplastic lesions of rat liver after subletal dose of N-nitrosomorpholine. Eur J Cancer 15: 189-196, 1979.
12. Lans M, de Gerlache J, Taper H, Préat V and Roberfroid M: Phenobarbital as a promotor in the initiation/selection process of experimental rat hepatocarcinogenesis. Carcinogenesis 4: 141-144, 1983.
13. Cleaver JE, Bootsma D and Friedberg E: Human diseases with genetically altered DNA repair processes. Genetics 79: 215-225, 1975.
14. Taper HS: Induction of deficient acid DNase activity in mouse interfollicular epidermis by croton oil as a possible tumor-promoting mechanism. Z Krebsforsch 90: 197-210, 1977.
15. Fort L, Taper HS and Brucher JM: Morphological alterations and focal deficiency of the histochemical activity of acid and alkaline nucleases in rat liver after chronic administration of phenobarbital. Beitr Pathol 161: 363-375, 1977.
16. Taper H S, Lans M, de Gerlache J, Fort L and Roberfroid M: Morphological alterations and DNase deficiency in phenobarbital promotion of N-nitrosomorpholine initiated rat hepatocarcinogenesis. Carcinogenesis 4: 231-234, 1983.
17. Taper H, de Gerlache J, Lans M, Preat V and Roberfroid M: Estrogens and primary liver tumors. In: Hormones and Sexual Factors in Human Cancer. Wolff JP and Scott JS (eds). London, Elsevier Science Publ., pp. 163-174, 1984.
18. Taper, HS, Brucher JM and Doyen G: Histochemical study on alkaline and acid nucleases activity in the human brain compared to the incidence of malignant tumors. J Neurol Sci 12: 69-82, 1971.
19. Fort L and Taper HS: L'activité histochimique des nucleases alcalines et acides comparée à l'incidence des carcinomes dans le système digestif du rat. Path Eur 4: 41-57, 1969.
20. Fort L and Taper HS: Nucleases activity in different segments of the human digestive tube compared to the incidence of carcinomas (histochemical study). Histochemie 20: 150-158, 1969.
21. Taper HS: Reversibility of acid and alkaline deoxyribonuclease deficiency in malignant tumor cells. J Histochem Cytochem 29: 1053-1060, 1980.
22. Taper HS, Deckers CO and Deckers-Passau LO: Increase in nuclease activity as a possible means for detecting tumor cell sensitivity to anticancer agents. Cancer 47: 523-529, 1981.
23. Avall-Lundqvist E, Economidou-Karaoglou A, Sjovall K, Lans M, Taper HS, Roberfroid M, and Enneroth P: Serum alkaline DNase activity in normal or non hospitalized individuals. Clin Chim Acta 185: 35-44, 1989.
24. Dewez B, Lans M, Allaeys V, Karaoglou A, Taper HS and Roberfroid M: Serum alkaline deoxyribonuclease activity, a sensitive marker for the therapeutic monitoring of cancer patients: Methodological aspects. Europ J Clin Chem Biochem 31: 793-797, 1993.
25. Economidou-Karaoglou A, Opsomer M, Petit G, Lans M and Roberfroid M: Variations in serum alkaline DNase activity: A new means for therapeutic monitoring of malignant lymphomas. Cancer 61: 1838-1843, 1988.
26. Economidou-Karaoglou A, Opsomer M, Petit G, Lans M, Taper HS and Roberfroid M: Characteristic variations of serum alkaline DNase activity in relation to response to therapy and tumor prognosis in human lung cancer. Eur J Cancer Clin Oncol 24: 1337-1343, 1988.
27. Economidou-Karaoglou A, Lans M, Taper HS, Michaux JL, and Roberfroid M: Variations in serum alkaline DNase activity: A new means to access early detection of relapse in patients treated for acute nonlymphoblastic leukaemia. Blood 74: 2730-273, 1989.
28. Economidou-Karaoglou A, Brasseur F, Lans M, Taper HS and Roberfroid M: Variations in serum alkaline DNase activity in rats during growth and treatment of tumors sensitive or resistant to therapy. Int J Cancer 43: 956-959, 1989.
29. Economidou-Karaoglou A, Opsomer M, Lans M, Taper HS, Deckers C and Roberfroid M: Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer. Acta Oncol 29: 163-166, 1990.
30. Roullet B, Labadie M, Taper HS, Lans M, Economidou-Karaoglou A, Dewez B, Roberfroid M, Berdah JF, Bachellerie-Rhein B, Clavere P et al: Valeur predictive des variations de l'activité sérique de la DNase alkaline dans le prognostic des cancers des voies aérodigestives supérieures traités par chimiothérapie. Bull Cancer 77: 675-680, 1990.
31. Taper HS, Lans M, Economidou A, de Gerlache J and Roberfroid M: A possible test of therapeutic prognosis of human tumors based on the detection of serum alkaline DNase variations. Anticancer Res 5: 600, 1985.
32. Taper HS, de Gerlache J, Lans M and Roberfroid M: Variations in serum DNase activity: A possible test for therapeutic prognosis of human tumors. Anticancer Res 6: 949-956, 1986.
33. 3 vitamin pre-treatment. Int J Cancer 40: 575-579, 1987.
34. Cappucino JG, Brown GF, Mountain SM, Spencer S and Tarnowski GS: Chemotherapeutic studies on the new transplantable mouse liver tumor (Taper liver tumor). Cancer Res 26: 689-694, 1966.
35. 3 pretreatment in a mouse tumor resistant to Oncovin. Anticancer Res 12: 1651-1654, 1992.
36. 3) treatment on human tumor cell growth in vitro. II. Synergism with combined chemotherapy action. Anticancer Res 13: 103-106, 1993.
37. 3) treatment on human tumor cell growth in vitro. Cancer 63: 901-906, 1989.
38. 3 in mice bearing solid, transplantable tumor. Anticancer Res 16: 499-505, 1996.
39. 3 combination. Life Sci 75: 955-967, 2004.
40. 3 combinations against human prostatic carcinoma cells. Scanning Microscop Intern 9: 159-173, 1995.
41. 3 combinations against prostatic carcinoma cells. Tissue Cell 28: 687-701, 1996.
42. 3-induced oxidative stress in human prostate tumor cells: mitochondrial ultrastructural alterations. Microscopy A. Microanalysis 3(suppl 2): 23-24, 1997.
43. 3 against human prostate carcinoma cell lines. Cell Biol Int 20: 787-797, 1996.
44. 3 on human urologic tumor cell lines. Life Sciences 59: 1389-1400, 1996.
45. Sinha BK and Mimmaugh EG: Free radicals and anticancer drug resistance. Oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Rad Biol Med 8: 567-581, 1990.
46. Cameron E, Pauling L and Leibovitz B: Ascorbic acid and cancer: A review. Cancer Res 39: 663-681, 1979.
47. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Huffer LJ, Levine M: Intravenously administered vitamin C as cancer therapy: three cases. Canad Med Assoc J 174: 937-942, 2006.
48. 3 on human bladder carcinoma T24 cells. Scanning 20: 564-575, 1998.
49. Kauffman SJ: Apoptosis. Pharmacological implications and therapeutic opportunities. In: Advances in Pharmacology 41, San Diego, Academic Press, 1997.
50. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555-556, 1980.
51. 3 combination. J Histochem Cytochem 49: 109-119, 2001.
52. 3 treatment. Microsc Microanal 9: 311-329, 2003.
53. 3 in cancer treatment. Cur Med Chem 9: 2271-2285, 2002.
54. 3 kills cancer cells mainly by autoschisis, a novel form of cell death. Basis for their potential use as adjuvants in cancer therapy. Eur J Med Chem 38: 451-457, 2003.
55. Verrax J, Cadrobbi J, Marques C, Taper HS, Habraken Y, Piette J and Buc Calderon P: Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3- independent form of cell death. Apoptosis 9: 225-235, 2004.
56. 3 (menadione) as auxiliary therapy in cancer treatment. Med Chem Rev 2: 277-282, 2005.
57. Verrax J, Stockis J, Tison A, Taper HS and Buc Calderon P: Oxidative stress by ascorbate-menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumor growth in nude mice. Biochem Pharmacol 72: 671-680, 2006.
58. Verrax J, Vanbever S, Stockis J, Taper HS and Buc Calderon P: Role of glycolysis inhibition and poly (ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/ menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int J Cancer 120: 1192-1197, 2007.
59. Verrax J, Taper HS and Buc Calderon P: Targeting cancer cells by an oxidant-based therapy. Curr Mol Pharmacol 1: 80-92, 2008.
60. 3 sensitize human urothelial tumors to gemcitabine. J Urol 176: 1642-1647, 2006.